Last reviewed · How we verify
LN-145-S1
At a glance
| Generic name | LN-145-S1 |
|---|---|
| Also known as | TIL, autologous tumor infiltrating lymphocytes |
| Sponsor | Iovance Biotherapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (PHASE2)
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (PHASE2)
- Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LN-145-S1 CI brief — competitive landscape report
- LN-145-S1 updates RSS · CI watch RSS
- Iovance Biotherapeutics, Inc. portfolio CI